Expression of multiple alpha1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction.
Previous work has shown that the genes encoding each alpha1-adrenoceptor subtype are coexpressed throughout the peripheral vascular system. We have evaluated subtype-selective antibodies as tools to determine the extent of protein expression in arteries. The alpha1A-, alpha1B-, and alpha1D-adrenoceptors were detected in the medial layer of the aorta, caudal, femoral, iliac, renal, superior mesenteric, and mesenteric resistance arteries. In Rat1 fibroblasts expressing each subtype, immunoreactivity was noted both on the cell surface and in a perinuclear orientation. Intense alpha1B-adrenoceptor immunostaining was similarly localized in cultured femoral and renal vascular smooth muscle cells. Although the cellular localization appeared to be the same, immunoreactivity obtained with alpha1A- and alpha1D-adrenoceptors was much less intense than that with the alpha1B-adrenoceptor. The alpha1A-adrenoceptor selective agonist A-61603 was 22-fold more potent in activating renal artery contraction when compared with the femoral artery. The expression of each alpha1-adrenoceptor was significantly decreased by in vivo application of antisense oligonucleotides targeted against each subtype. Inhibition of the expression of only one, the alpha1A in renal and the alpha1D in femoral arteries, reduced the contractile response to naphazoline. The results show: 1) subtype-selective antibodies can be used in tissues and cell culture to localize the alpha1-adrenoceptor subtypes, 2) in addition to expression on the cell surface, the alpha1-adrenoceptors are expressed intracellularly, and 3) despite expression of all adrenoceptors, a single subtype mediates the contractile response in the femoral and renal arteries.
Hrometz
S L
SL
The Department of Pharmacology, The University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Edelmann
S E
SE
McCune
D F
DF
Olges
J R
JR
Hadley
R W
RW
Perez
D M
DM
Piascik
M T
MT
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D000918:Antibody Specificity; D002478:Cells, Cultured; D005263:Femoral Artery / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D018613:Microscopy, Confocal; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D009278:Naphazoline / Q000494:pharmacology; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018340:Receptors, Adrenergic, alpha-1 / Q000096:biosynthesis* / Q000276:immunology / Q000502:physiology; D012077:Renal Artery / Q000166:cytology / Q000187:drug effects / Q000378:metabolism
D000316:Adrenergic alpha-Agonists; D016376:Oligonucleotides, Antisense; D018340:Receptors, Adrenergic, alpha-1; D009278:Naphazoline